Legal Opinion
In re Suboxone (Buprenorphine Hydrochloride & Naloxone) Antitrust Litigation
District Court, E.D. Pennsylvania
Decided December 3, 2014No. MDL No. 2445, 13-MD-2445PublishedCited by 35 opinions
1Opinion of the Court
*672 MEMORANDUM OPINION
GOLDBERG, District Judge.
This multidistrict litigation raises the following question: can a pharmaceutical' company marketing brand-name prescription drugs be subject to antitrust liability for engaging in what has been referred to as a “product hopping” scheme? Plaintiffs urge that the answer to this question is “yes,” and allege that as the period of exclusivity on the brand-name drug, Su-boxone, expired and generic versions of that drug were to become available, Reck-itt Benekiser, Inc. effectuated inconsequential changes to the Suboxone dosage form to prevent…
2Cases cited130 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Lewis v. CaseySupreme Court of the United States · 1996
- Amchem Products, Inc. v. WindsorSupreme Court of the United States · 1997
125 more not listed; retrieve them via the Exa API.
3Cited by35 opinions
- New York Ex Rel. Schneiderman v. Actavis PLCCourt of Appeals for the Second Circuit · 2015
- Apotex Inc. v. Acorda Therapeutics, Inc.Court of Appeals for the Second Circuit · 2016
- In re Broiler Chicken Antitrust Litig.District Court, E.D. Illinois · 2017
- In re Packaged Seafood Products Antitrust LitigationDistrict Court, S.D. California · 2017
- In re Generic Pharm. Pricing Antitrust Litig.District Court, E.D. Pennsylvania · 2019
30 more not listed; retrieve them via the Exa API.